2-{[2-(4-Chlorophenyl)-1H-benzimidazol-1-yl]acetyl}-N-ethylhydrazinecarbothioamide

ID: ALA4474651

PubChem CID: 155537104

Max Phase: Preclinical

Molecular Formula: C18H18ClN5OS

Molecular Weight: 387.90

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  CCNC(=S)NNC(=O)Cn1c(-c2ccc(Cl)cc2)nc2ccccc21

Standard InChI:  InChI=1S/C18H18ClN5OS/c1-2-20-18(26)23-22-16(25)11-24-15-6-4-3-5-14(15)21-17(24)12-7-9-13(19)10-8-12/h3-10H,2,11H2,1H3,(H,22,25)(H2,20,23,26)

Standard InChI Key:  LKJKDOATIHYLHM-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 28  0  0  0  0  0  0  0  0999 V2000
    7.8780   -4.7283    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.3274   -5.3285    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.6323   -3.9482    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8317   -3.7725    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.1829   -3.3439    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    6.5860   -2.9924    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7896   -2.8166    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5732   -6.1086    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3737   -6.2844    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.0225   -6.7129    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7847   -8.1460    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2573   -8.8153    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.0373   -8.5654    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0426   -7.7483    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2683   -7.4888    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.7417   -8.9780    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4555   -8.5775    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4607   -7.7604    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7563   -7.3437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9676   -8.1460    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5509   -8.8457    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7337   -8.8405    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3332   -8.1262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7458   -7.4265    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5630   -7.4317    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5161   -8.1262    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  3  4  1  0
  3  5  2  0
  1  3  1  0
  6  7  1  0
  4  6  1  0
  8  9  2  0
  8 10  1  0
 11 12  2  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 11 15  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 14 19  2  0
 13 16  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 20 25  2  0
 23 26  1  0
 11 20  1  0
 10 15  1  0
  2  8  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4474651

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 387.90

Molecular Weight (Monoisotopic): 387.0921

AlogP: 2.87

#Rotatable Bonds: 4

Polar Surface Area: 70.98

Molecular Species: NEUTRAL

HBA: 4

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 10.95

CX Basic pKa: 4.94

CX LogP: 3.33

CX LogD: 3.33

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.47

Np Likeness Score: -2.27

References

1. Celik İ, Ayhan-Kılcıgil G, Guven B, Kara Z, Gurkan-Alp AS, Karayel A, Onay-Besikci A..  (2019)  Design, synthesis and docking studies of benzimidazole derivatives as potential EGFR inhibitors.,  173  [PMID:31009910] [10.1016/j.ejmech.2019.04.012]

Source

Source(1):

• Scientific Literature